• 대한전기학회논문지:시스템및제어부문D
• /
• 제54권4호
• /
• pp.274-283
• /
• 2005

Coronary Perfusion Pressure(CPP) is known for the most important parameter related to the Return of Spontaneous Circulation (ROSC), however, clinically measuring CPP is difficult either invasive or non-invaisive method. En this paper, we analyze the correlation between the extracted parameter from VF ECG wave and the CPP with the statistical method, and predict CPP value using the extracted parameters within significance level. the extracted parameters are median frequency(MF), peak frequency(PF), average segment amplitude(ASA), MSA(maximum segment amplitude), Two parameters, MF, and ASA are selected in order to predict CPP value with general regression neural network, and then we evaluated the agreement statistics between the simulated CPP and the measured CPP. In conclusion, the mean and variance of the difference between the simulated CPP and the measured CPP are 8.9716±1.3526 mmHg, and standard deviation 6.4815 mmHg with one hundred-times training and test results. the simulated CPP and the measured CPP are agreed with the overall accuracy $90.68\%$ and kappa coefficient $81.14\%$ as a discriminant parameter of ROSC.

• 한국임상수의학회지
• /
• 제27권5호
• /
• pp.573-578
• /
• 2010

4살 된 시츄개(체중 5 kg)가 청색증을 동반한 심한 호흡곤란과 운동 불내성으로 내원하였다. 진단검사를 통해 우-좌형 동맥관 개존증과 비정상적인 대동맥 분지장애(좌총경정맥 잔존) 및 세균성 폐렴이 확진되었다. 환자는 이뇨제, 항생제, 산소요법 및 고칼륨혈증에 대한 처치에 불구하고 심한 고칼륨혈증에 의한 심실성 부정맥과 탈수에 의해 폐사하였다. 부검을 통해 심한 대동맥궁 확장과 비정상적인 좌총경정맥 분지 잔존을 확인하였다.

• Journal of Yeungnam Medical Science
• /
• 제31권2호
• /
• pp.122-126
• /
• 2014

Coronary vasospasm is one of the fatal complications that may occur in patients undergoing open heart surgery. To date, however, there are not many cases in this series and no definite pathophysiology has been documented. We experienced a case of coronary artery vasospasm after atrial septal defect (ASD) surgery and then successfully treated it with both transbrachial intraaortic balloon pump and percutaneous cardiopulmonary support. Only several hours after ASD surgery, the patient exhibited the cardiovascular collapse, the ST-segment elevation, followed by ventricular fibrillation and normal coronary angiography findings. It is important to make a differential diagnosis of coronary artery vasospasm in patients presenting with ST-segment elevation who had no notable coronary artery diseases. This case indicates that clinicians should be aware of the possibility that the coronary artery vasospasm may also occur in patients undergoing ASD surgery.

• Journal of Chest Surgery
• /
• 제54권6호
• /
• pp.449-453
• /
• 2021

The 2020 American College of Cardiology focused update on the mitral regurgitation (MR) pathway provides an excellent summary of the decision-making trees in the treatment of severe MR, in which 2 main branches of the flowchart are suggested depending on whether MR is primary or secondary. Surgery is suggested as preferable over transcatheter edge-to-edge repair (TEER) in primary MR that needs intervention. The decision-making for secondary MR generally prioritizes TEER over surgery according to the guidelines, but further stratification is necessary based on the pathophysiologic mechanisms of MR. TEER is probably the more suitable option in secondary MR caused by left ventricular dysfunction or dilatation, given the high perceived surgical risks, despite the lack of sufficient evidence in support of overt clinical benefits from surgical therapy in these patients. In atrial functional MR associated with atrial fibrillation (AF), however, concomitant ablation of AF seems to be a desirable option, as it has been demonstrated to be a key factor leading to improved survival, reduced stroke risk, and more durable mitral and tricuspid function in patients undergoing mitral surgery. Therefore, atrial functional MR requiring intervention may be best treated by surgical therapy that combines mitral repair and AF ablation in the majority of patients. This particular issue, however, needs further research to obtain scientific evidence to guide optimal management strategies.

• Journal of Yeungnam Medical Science
• /
• 제3권1호
• /
• pp.279-285
• /
• 1986

가토의 Ouabain유발 부정맥에 미치는 Carbamazepine의 영향을 검색한 결과 다음과 같은 결론을 얻었다. 1. Ouabain을 지속적으로 정맥 주사하여 64+$8.8{\mu}g/kg$이 투여되었을 때 부정맥이 발생 했으며, 이 양을 부정맥 유발 가능용량으로 정했다. 2. Ouabain $64{\mu}g/kg$을 단회 정맥 주사했을 때 발생한 부정맥은 약 7~9분간 지속된 후 모든 예에서 자연 소실되었고, 정상 심박동으로 회복된 지 20분 후 다시 동량의 Ouabain을 정맥 주사했을 때 모든 예에서 다시 나타났다. 3. 부정맥 유발 용량($64{\mu}g/kg$)의 Ouabain을 단회 정맥 주사한 후 부정맥이 나타난 것을 관찰 즉시 Carbamazepine을 투여한 결과 즉시 정상 신박동으로 환원되었으며 어느 정도 지속된 후 모든 예에서 부정맥이 발생했으나 즉시 동량의 Carbamazepine 투여로 다시 정상 심박동으로 환원되었다. 한편, Carbamazepine의 양이 증가되면서 항 부정백 작용의 기간은 길어졌으나 항 부정맥 작용없이 사망한 예가 많아졌다. 4. Carbamazepine을 단독 투여 해 본 결과 그 양이 증가함에 따라 심한 서맥, A-V block, 심방 세동 등이 나타나면서 심장이 정지함을 볼 수 있었다. 이상의 실험 결과로 미루어 Carbamazepine은 Ouabain의 독작용에 의한 심한 부정맥을 일시적으로 억제할 수 있으며, 보다 대량에서는 그 항 부정맥 작용이 보다 오래 지속할 수 있으나 Carbamazepine 자체의 심장에 대한 부작용이 발현될 위험이 존재한다고 생각된다.

• Journal of Chest Surgery
• /
• 제40권5호
• /
• pp.351-355
• /
• 2007

배경: 급성 심근경색증에 합병된 심실중격 결손은 내과적 치료만으로는 $85\sim90%$의 높은 사망률을 보이는 질환으로서, 본 병원에서의 외과적 치료 경험을 분석하였다. 대상 및 방법: 1996년 8월부터 2006년 8월 사이에 급성 심근경색증 후 합병된 심실중격 결손으로 수술적 치료를 시행한 11예를 대상으로 후향적으로 의무기록을 검토하였다. 남자가 4명, 여자가 7명이었으며 평균연령은 $70{\pm}11$ (범위, $50\sim84$)세였다. 심실중격 결손의 위치는 전중격 결손이 7예, 후중격 결손이 4예 있었다. 심실중격 결손은 급성 심근경색 후 $2.0{\pm}1.3$ (범위, $1\sim5$)일째에 발견되었으며 심실중격 결손의 진단 후 $2.4{\pm}2.7$ (범위, $0\sim8$)일째에 수술을 시행하였다. 모든 환자에서 수술전 심초음파와 관상동맥조영술을 시행하여 심실중격 결손의 위치, 심실 기능, 그리고 관상동맥 병변을 파악하였으며, 수술 전에 대동맥내 풍선 펌프를 삽입한 경우가 10예 있었다. 결과: 11예 모두에서 infarct exclusion 술식을 시행하였고, 8예에서는 관상동맥우회술을 함께 시행하였으며 평균 문합수는 $1.0{\pm}0.8$개였다. 수술 사망은 1예였으며 수술 후 초음파 소견에서 잔여 단락이 발견되었던 2예에서는 첩포의 누출에 대해 재수술을 시행하였다. 그 밖의 합병증으로는 일시적인 심방세동(7예), 발작성 심실상성빈맥(1예), 저심박출증(3예), 재수술이 필요했던 출혈(2예), 흉골 지연봉합(2예), 급성 신부전(2예), 폐렴(1예), 대동맥내 풍선펌프로 인한 혈전색전증(1예),수술 후 섬망(2예) 등이 있었다. 생존한 10명의 환자들 중 1명을 제외한 나머지 9명의 환자에서 $38{\pm}40$개월간의 추적관찰이 되었는데, 추적 관찰 기간 중에 3명이 사망하였고 생존한 6명의 환자는 모두 양호한 상태(NYHA 기능등급, $I{\sim}II$)를 보였으며, 그 중 3명에서는 혈역학적으로 큰 의미가 없는 잔여단락이 있었다. 결론: 급성 심근경색증 후 심실중격 결손은 수술위험도가 높은 질환이지만, 수술 전 대동맥내 풍선펌프를 삽입하고 조기에 심실중격 결손부의 infarct exclusion 술식과 함께 관상동맥우회술을 시행함으로써 만족할 만한 수술 및 중기 결과를 얻을 수 있었다.

• Journal of Chest Surgery
• /
• 제31권11호
• /
• pp.1037-1042
• /
• 1998

연구배경 : 승모판의 노출을 위한 여러 접근방식 중, 확장시킨 경중격 절개방식은 다른 방법에 비하여 쉽고 빠르게 승모판막에 접근할 수 있으며 모든 판막구조물의 노출이 잘 되어 월등한 방법이라 할 수 있다. 그러나, 이러한 장점에도 불구하고 혹자는 광범위한 절개 및 동방결절 동맥의 손상으로 치명적인 부정맥이 발생하지 않을까 우려하여 이용을 기피하는 경향이 있고 반론을 재기하는 사람들도 많이 있다. 재료 및 방법 : 따라서 본 교실에서는 1992년 9월부터 1997년 7월까지, 모두 80명의 환자에서 확장시킨 경중격 절개방식을 적용한 후, 어떠한 장·단점이 있나 알아보고 수술후 심장율동에 미치는 영향을 알아보았다. 결과 : 78명의 환자가 승모판 치환수술을 받았고 2명은 좌심방 점액종 제거수술을 받았다. 승모판 치환수술을 받은 78명중 38명의 환자가 동시에 대동맥판 치환수술(n=22), 삼첨판성형술(n=14), 관상동맥 우회로조성술(n=1), 심실중격결손증 교정수술(n=1) 등을 받았다. 수술 후 총 74명에서 평균 23.3개월간 외래추적관찰을 하였다. 병원사망률은 3.8%(3례)를 보였고, 술전 심방세동을 보이던 46명의 환자중 1명이 수술후 정상 동조율로 전환 되었으며, 술전 정상동조율을 보였던 34명은 술후에도 계속 정상 동조율을 유지하였다. 평균 대동맥 차단시간은 71분이었고, 승모판막 단일 수술인 경우는 평균 62분이었다. 수술후 가장 흔한 부정맥은 서맥으로 일시적인 심장조율로 호전되었으며 다른 수술과 연관된 특별한 합병증은 없었다. 결론 : 승모판막수술시 확장시킨 경중격 절개방식의 적용으로 특별한 합병증 없이 좋은 결과를 얻을 수 있고 특히 좌심방의 크기가 작은 경우 많은 도움이 될 것으로 사료된다

• Journal of Chest Surgery
• /
• 제25권11호
• /
• pp.1318-1326
• /
• 1992

Backgroud. To determine the influence of age at operation upon surgical outcome in patients with isolated secundum atrial septal defect, retrospective clinical analysis was done. Material and method. From June, 1976 to December, 1991, 146 patients, 63 male and 83 female patients ranging in age from 13 months to 56 years, were operated on for isolated secundum atrial septal defect. The patients were divided into 3 groups according to their age at operation: Group I [<20 years old], 91 patients[62.3%]; Group II [21 to 40 years old], 44 patients[30.1%]; GroupIII[>41 years old], 11 patients[7.6%]. Significant differences in clinical features, hemodynamic function, early and late results between age groups were speculated. Results. One hundred thirty-one patients[89.6%] were symptomatic at the time of operation, the most common symptoms being dyspnea on exertion, recurrent respiratory infection, palpitation and chest pain. Patients in NYHA class III or IV were 3.3% in group I, 25% in groupIII, and 54.5% in group Ill. Hemodynamic data was available for 138 patients [94.5%]. Significant pulmonary hypertension [MPA systolic pressure $^3$ 40mmHg] was noted in 22 patients [15.9%]. Patients with pulmonary vascular disease [Rp/Rs>1.25] were 2% in group I, 7.3% in group Il, and 9.1% in groupIII. But there were no significant differences between the age groups in the size of the shunt or the ratio of pulmonary to systemic flow. Atrial septal defects were closed with direct suture in 144 patients and patch repair was performed in 2 patients with high defect. Atrial arrhythmia [8.2%] was the most common postoperative complication. The mean [LSD] duration of follow-up in all patients was 16$\pm$22 months [range, 1~96 months]. Functional result was excellent regardless of the age groups. During follow-up period, late cardiovascular events were arrhythmia [7 cases], reoperation for recurrent ASD [2 cases], and premature late death due to bacterial endocarditis [1 case]. Incidence of preoperative and late atrial fibrillation was significantly higher in older age group. Conclusion. Age at operation is one of the most important predictor of early and late surgical outcome with its impact on the following factors : 1] hemodynamic alterations and ventricular dysfunction due to longstanding volume and pressure overload, 2] pulmonary vascular disease, and 3] atrial arrhythmia including atrial fibrillation as a result of atrial dilatation. Therefore, among patients with surgically repaired atrial septal defects, those operated on over the age of 20 require careful supervision on the long-term basis.

• Journal of Chest Surgery
• /
• 제16권4호
• /
• pp.602-614
• /
• 1983

Six hundred fourteen consecutive cases of bioprosthetic cardiac valve replacement performed during the period from March 1976 through December 1982 were reviewed. A total of 748 tissue valves [534 Ionescu-Shiley valves, 144 Hancock valves, 46 Angell-Shiley, and 24 Carpentier-Edwards] were implanted in 610 patients. Of these, 477 had single valve replacements [403 mitral, 60 aortic, and 14 tricuspid] including three REDO MVR and one REDO AVR. The remaining 129 had double valve replacements [95 AVR and MVR and 34 MVR and TVR] and 8 had triple valve replacement.592 cases were evaluated. Overall early mortality rate [within 30 days of operation] was 7.1% [6.2% in single valve replacement, 10.2% in double valve replacement, and 16.7% in triple valve replacement]. Leading causes of mortality were low cardiac output or myocardial failure and ventricular arrhythmias. The follow-up period was from one month to 7 years with a cumulative follow-up of 906.6 patient-years [mean 1.53 years]. The late mortality was 1.6%, 3.9%, 0%, 2.6%, 6.6% and 2.0% per patient-year for MVR, AVR, TVR or triple valve replacement, AVR+MVR, MVR+TVR and total, respectively. Actuarial analysis of late results including early mortalities indicates an expected survival rate of 87.6+1.8% at 3 years and 85.92.4% at 7 years for all cases. We also analyzed actuarial survival rate between groups of each valve replacement [AVR, TVR, Double valve, and Triple valve] and the tissue valve groups in MVR. We experienced 7 cases [0.77% per patient-year] of confirmed endocarditis, two of which were fatal. Valve failure-free rates calculated according to the confirmed cases were 97.5% at 4 years, 87.5% at 7 years, and 88.3% at 6 years for Ionescu-Shiley, Hancock and Angell-Shiley valves, respectively. The occurrence rate of thromboembolism was 2.0% per patient-year in total cases, although almost all the patients were given anticoagulant therapy for one year. The occurring rate in MVR was 1.5% and 2.7% per patient-year for Ionescu-Shiley and Hancock valve groups, respectively. The difference in actuarial rate free from thromboemboli between Ionescu-Shiley and Hancock groups was statistically significant [P value less than 0.001]. Thromboembolic events beyond the period of anticoagulation therapy mainly occurred in patients with atrial fibrillation. The actuarial thromboemboli free survival was 95.71.4% at 3 years and 80.17.3% at 7 years. The incidence of hemorrhagic complications was 1.2% per patient-year [fatality 0.55% per patient-year] for anticoagulated patients. Although our clinical data favorably compares with results from other reports, our results suggest that anticoagulant therapy be given on a short-term basis or not at all to hemodynamically stable patients. Long-term therapy with antiplatelet drugs is probably inevitable with patients who have thromboembolic risk factors [such as atrial fibrillation].

• Korean Circulation Journal
• /
• 제53권7호
• /
• pp.425-451
• /
• 2023

Most patients with heart failure (HF) have multiple comorbidities, which impact their quality of life, aggravate HF, and increase mortality. Cardiovascular comorbidities include systemic and pulmonary hypertension, ischemic and valvular heart diseases, and atrial fibrillation. Non-cardiovascular comorbidities include diabetes mellitus (DM), chronic kidney and pulmonary diseases, iron deficiency and anemia, and sleep apnea. In patients with HF with hypertension and left ventricular hypertrophy, renin-angiotensin system inhibitors combined with calcium channel blockers and/or diuretics is an effective treatment regimen. Measurement of pulmonary vascular resistance via right heart catheterization is recommended for patients with HF considered suitable for implantation of mechanical circulatory support devices or as heart transplantation candidates. Coronary angiography remains the gold standard for the diagnosis and reperfusion in patients with HF and angina pectoris refractory to antianginal medications. In patients with HF and atrial fibrillation, longterm anticoagulants are recommended according to the CHA₂DS₂-VASc scores. Valvular heart diseases should be treated medically and/or surgically. In patients with HF and DM, metformin is relatively safer; thiazolidinediones cause fluid retention and should be avoided in patients with HF and dyspnea. In renal insufficiency, both volume status and cardiac performance are important for therapy guidance. In patients with HF and pulmonary disease, beta-blockers are underused, which may be related to increased mortality. In patients with HF and anemia, iron supplementation can help improve symptoms. In obstructive sleep apnea, continuous positive airway pressure therapy helps avoid severe nocturnal hypoxia. Appropriate management of comorbidities is important for improving clinical outcomes in patients with HF.